Chiu CH - Search Results

1

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Wang M, Yang JC, Mitchell PL, Fang J, Camidge DR, Nian W, Chiu CH, Zhou J, Zhao Y, Su WC, Yang TY, Zhu VW, Millward M, Fan Y, Huang WT, Cheng Y, Jiang L, Brungs D, Bazhenova L, Lee CK, Gao B, Xu Y, Hsu WH, Zheng L, Jänne PA. Wang M, et al. Among authors: chiu ch. Cancer Discov. 2022 Jul 6;12(7):1676-1689. doi: 10.1158/2159-8290.CD-21-1615. Cancer Discov. 2022. PMID: 35404393 Free PMC article.

2

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.

Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Chiu CH, et al. Lung Cancer. 2005 Jan;47(1):129-38. doi: 10.1016/j.lungcan.2004.05.014. Lung Cancer. 2005. PMID: 15603863 Clinical Trial.

3

Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.

Shih YN, Chiu CH, Tsai CM, Perng RP. Shih YN, et al. Among authors: chiu ch. J Chin Med Assoc. 2005 Apr;68(4):183-6. doi: 10.1016/S1726-4901(09)70246-1. J Chin Med Assoc. 2005. PMID: 15850069 Free article.

4

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.

Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, Chen YM, Perng RP, Tsai SF, Tsai CM. Chou TY, et al. Among authors: chiu ch. Clin Cancer Res. 2005 May 15;11(10):3750-7. doi: 10.1158/1078-0432.CCR-04-1981. Clin Cancer Res. 2005. PMID: 15897572

5

Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.

Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Lin WC, et al. Among authors: chiu ch. Lung Cancer. 2006 Nov;54(2):193-9. doi: 10.1016/j.lungcan.2006.07.013. Epub 2006 Sep 22. Lung Cancer. 2006. PMID: 16996166 Clinical Trial.

6

Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.

Chang GC, Tsai CM, Chen KC, Yu CJ, Shih JY, Yang TY, Lin CP, Hsu JY, Chiu CH, Perng RP, Yang PC, Yang CH. Chang GC, et al. Among authors: chiu ch. J Thorac Oncol. 2006 Jul;1(6):520-5. J Thorac Oncol. 2006. PMID: 17409911 Free article.

7

Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.

Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Perng RP. Chiu CH, et al. Lung Cancer. 2007 Aug;57(2):213-21. doi: 10.1016/j.lungcan.2007.02.016. Epub 2007 Apr 20. Lung Cancer. 2007. PMID: 17449138

8

Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?

Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai CL, Hsiao SY, Chen YM, Chang KT. Tsai CM, et al. Among authors: chiu ch. J Thorac Oncol. 2011 Mar;6(3):559-68. doi: 10.1097/JTO.0b013e3182021ff5. J Thorac Oncol. 2011. PMID: 21258258 Free article.

9

Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.

Tsai CM, Chiu CH, Chang KT, Chen JT, Lai CL, Chen YM, Hsiao SY. Tsai CM, et al. Among authors: chiu ch. J Thorac Oncol. 2012 Aug;7(8):1218-27. doi: 10.1097/JTO.0b013e318258cf17. J Thorac Oncol. 2012. PMID: 22659964 Free article.

10

Erlotinib in patients with advanced lung squamous cell carcinoma.

Chiang CL, Tsai CM, Chou TY, Chen YM, Lai SL, Shih JF, Chiu CH, Lee YC. Chiang CL, et al. Among authors: chiu ch. Cancer Chemother Pharmacol. 2013 Jan;71(1):203-8. doi: 10.1007/s00280-012-1997-5. Epub 2012 Oct 10. Cancer Chemother Pharmacol. 2013. PMID: 23053274

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,330 results

Search Page